CD274 and tuberculosis: Immune checkpoint blockade has been shown to reinvigorate immune responses (5), and following its successful application in cancer therapies, such as the targeting of the PD-1/PDL-1 checkpoint in lung cancer immunotherapies (6), is considered a potential therapeutic approach for boosting T cell immunity in chronic infections like TB (7).